BMS-986521

BMS-986521 is an investigational oral small molecule developed by Bristol Myers Squibb. It functions as an antagonist of Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8), which are key components of the innate immune system involved in recognizing single-stranded RNA. Dysregulation of these receptors is strongly implicated in the pathogenesis of autoimmune and inflammatory diseases, such as systemic lupus erythematosus (SLE). The drug has been evaluated in a first-in-human Phase 1 clinical trial (NCT05481606) involving healthy adult participants to assess its safety, tolerability, and pharmacokinetics through single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, as well as to investigate food effects and various formulations.